All IPOs

Pramodini Medicare

SME · NSE listed
+1.69%
Listing gain
Price Band
₹110 – ₹118
Issue Size
₹69.04 Cr
1 lot at upper band
₹1,41,600
Lot Size
1,200
Open
12 Aug 2026
Close
14 Aug 2026
Allotment
—
Listing
19 Aug 2026

Scheduled dates

  1. Open
    12 Aug 2026
  2. Close
    14 Aug 2026
  3. Refund
    18 Aug 2026
  4. Demat credit
    18 Aug 2026
  5. Listing
    19 Aug 2026

Listing Performance

Listing Price
₹120
Listing Gain
+1.69%
Day Close
—
Current (LTP)
— (—)

GMP Trend*

Daily grey market premium (₹). Unofficial.

Latest GMP: ₹0 16 sessions

Subscription (times)

Latest per-category subscription · as of 14 Aug, 06:56 pm IST.

QIB 3.66x
NII 4.96x
BHNI 5.03x
SHNI 4.82x
RII 3.49x
Total 3.87x

About Pramodini Medicare

The company is a diagnostic service provider in India offering technology-enabled diagnostic services including radiology, clinical laboratory and nuclear medicine services to public hospitals, private hospitals, PSUs and medical colleges across tier I, II and III cities. The company operates through four key models: Public Private Partnership, Private Private Partnership, Strategic Partnership with PSUs, and Private Centres. As of the filing date, the company operates 16 diagnostic centres across 7 states and 14 cities in India, providing comprehensive diagnostic services from routine to specialized tests for disease prediction, early detection, diagnostic screening, confirmation and monitoring.

www.pramodinidiagnostics.com ↗

Strengths

  • Strategic presence across various states of India
    The company operates through 16 diagnostic centres across 7 states (Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NCR Delhi, Madhya Pradesh and Kerala) and 14 cities in India, providing a strong operational footprint and reputation for quality diagnostic services.
  • Diversified business models strengthening network
    The company operates across four key models: Public Private Partnership (7 centres), Private Private Partnership (3 centres), Strategic Partnership with PSUs (4 centres), and Private Centres (2 centres), providing diversified revenue streams and risk mitigation.
  • Technical capability with robust IT infrastructure
    The company deploys advanced equipment including 8 CT machines, 7 MRI machines, 20 X-ray machines, 1 PET CT, and maintains relationships with equipment vendors for favorable procurement terms and preferred vendor status.
  • Dedicated management team with significant industry experience
    The company is led by experienced professionals including Promoters Dr. Chalasani Kuldeep Kumar with over 2 decades of Radio-Diagnosis experience and Dr. Chalasani Kavitha with over 2 decades as obstetrician and gynaecologist.
  • Track record of revenue and financial performance
    The company demonstrated consistent revenue growth from ₹3,522.95 lakhs (FY 2024) to ₹6,228.75 lakhs (FY 2026) with EBITDA margin of 49.61% and PAT margin of 27.90% in FY 2026.
  • Diverse customer cum patient base
    The company serves diverse customer segments including B2G (61.46% revenue), B2B (20.82% revenue), and B2C (17.72% revenue) in FY 2026, enhancing service quality and market credibility.

Risk Factors

  • Dependence on Government PPP Arrangements
    The company derives 54.19% of revenue from Public Private Partnership arrangements with government authorities as of FY 2025-26. Any non-renewal, modification, or termination of MOUs, or delays in payments from government authorities, may materially affect business operations and financial condition.
  • Heavy Concentration on Radiology Services
    The company generates 97.05% of revenue from radiology services as of FY 2025-26, creating significant exposure to capital-intensive equipment requirements and regulatory compliance risks. This concentration exposes the company to disproportionate impact from disruptions or market shifts in the radiology domain.
  • Geographic Revenue Concentration in Andhra Pradesh
    The company derives 61.90% of revenue from Andhra Pradesh as of FY 2025-26. Any regional economic slowdown, political unrest, or reduced demand in this state could adversely affect business operations and financial performance.
  • Customer Concentration Risk
    The company's top customer accounts for 44.17% of revenue and top 10 customers contribute 64.83% of total revenue as of FY 2025-26. Loss of any major customer could significantly impact revenue growth and market reputation.
  • High Dependence on Government Revenue (B2G)
    Government arrangements (B2G) constitute 61.46% of revenue as of FY 2025-26. Changes in government policies, budget allocations, or termination of arrangements could materially affect business operations and financial condition.
  • Quality Standards and Medical Malpractice Liability
    Failure to maintain appropriate quality standards in diagnostic services could result in litigation, liability claims, and reputational damage. Inaccuracies in test results or equipment errors could lead to patient harm and substantial legal costs.
  • IT Systems and Cybersecurity Vulnerabilities
    The company relies heavily on information technology systems for conducting tests, transmitting results, and managing operations. System failures, cyber-attacks, or data breaches could disrupt operations and expose the company to regulatory action and financial liabilities.

Objects of the Issue

  • Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres
    The company intends to purchase and install medical equipments across existing diagnostic centres in Hubli, Manjeri, and Vijayawada, and establish a new diagnostic centre in Bangalore to expand capacity, improve service efficiency, and strengthen brand presence.
    45.15 crores
  • General corporate purposes and unidentified inorganic acquisition
    The company plans to evaluate inorganic growth opportunities through mergers and acquisitions to expand into new geographies, add service offerings, and consolidate market position, along with meeting general corporate expenses in the ordinary course of business.

Financial Snapshot

Annual values as reported in the offer document.

Year endRevenueRev. growthProfitProfit growthAssetsEquityOperating cash flow
31/03/202663.38+64.4%17.38+57.6%93.6253.1525.39
31/03/202538.55+7.7%11.03+59.2%56.4535.7722.12
31/03/202435.79—6.93—48.7824.759.85
Units: crores

Issue Details

Face Value
₹10
P/E
15.00
ROCE
42.00%
Shares / Lot
1,200
Minimum Bid
2,400 shares
Refund
18 Aug 2026
Credit to Demat
18 Aug 2026
ISIN
INE2JG601017
CIN
U85110AP2000PLC035231
Registrar
Purva Sharegistry (India) Pvt.Ltd.
Lead Managers
Smart Horizon Capital Advisors Pvt.Ltd.
Registered Office
D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India – 520002
RHP ↗DRHP ↗

Management

Dr. Chalasani Kuldeep KumarMD
Dr. Chalasani KavithaCEO
Ms. Chalasani Durga AashrithaCFO
Mr. A Ajay KumarCOO

* Grey Market Premium is unofficial, indicative data from unregulated grey-market dealers. It is not published by NSE, BSE, SEBI or the issuer, and is not a forecast of the listing price.